ELIZABETH SILVESTRI: Open Payments
NPI 1700079118 · SALEM, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,031 in 64 payments from 12 companies in 2025. Trend: 2023 $38 · 2024 $1,055 · 2025 $1,031
Food & beverage: $1,031
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $266 |
| Janssen Biotech, Inc. | 9 | $191 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 18 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| Ardelyx, Inc. | 3 | $66 |
| PFIZER INC. | 3 | $60 |
| Aimmune Therapeutics, Inc. | 2 | $50 |
| GENZYME CORPORATION | 2 | $45 |
| Novo Nordisk Inc | 2 | $45 |
| Gilead Sciences, Inc. | 1 | $23 |
Products named: TREMFYA, XIFAXAN, RINVOQ, CREON, Linzess, ENTYVIO, IBSRELA, ZENPEP.
Industry payments across NH — which companies pay providers there.
